CONMED Financial Statements
NYSE: CNMDHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CONMED revenue and earnings
In fiscal 2025, CONMED generated $1.37 billion in revenue, up 5.2% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $47.1 million (-64.5% year over year), for a net margin of 3.4% versus a median of 5.2% in the prior 5 years. Gross margin was 54.6% (down from 56.1%) and operating margin 7.5%.
Diluted earnings per share came in at $1.51, down from $4.25. Over the last 5 fiscal years, CNMD's revenue has grown at a 9.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
CONMED income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.37B | 1.31B | 1.24B | 1.05B | 1.01B | 862.46M | 955.10M | 859.63M | 796.39M | 763.52M |
| Revenue growth (YoY) | +5.18% | +5.00% | +19.06% | +3.45% | +17.18% | -9.70% | +11.11% | +7.94% | +4.31% | +6.17% |
| Cost of Revenue | 624.25M | 573.98M | 568.50M | 474.23M | 442.60M | 402.16M | 430.38M | 390.52M | 365.35M | 355.19M |
| Gross Profit | 750.48M | 733.03M | 676.25M | 571.25M | 568.04M | 460.30M | 524.72M | 469.11M | 431.04M | 408.33M |
| Operating Expenses | 647.85M | 532.71M | 555.64M | 501.19M | 458.32M | 414.29M | 445.60M | 397.81M | 384.11M | 370.65M |
| Research & Development | 55.88M | 54.43M | 52.60M | 47.15M | 43.56M | 40.47M | 45.46M | 42.19M | 32.31M | 32.25M |
| Selling, General & Admin | 591.97M | 478.28M | 503.04M | 454.04M | 414.75M | 373.82M | 400.14M | 355.62M | 351.80M | 338.40M |
| Operating Income | 102.62M | 200.33M | 120.60M | 70.05M | 109.72M | 46.01M | 79.11M | 71.31M | 46.94M | 37.68M |
| Interest Expense | 31.09M | 37.30M | 39.77M | 28.91M | 35.48M | 44.05M | 42.70M | 20.65M | 18.20M | 15.36M |
| Pretax Income | 71.12M | 163.03M | 80.83M | -70.86M | 73.11M | 1.60M | 31.23M | 50.65M | 28.73M | 19.38M |
| Income Tax | 24.06M | 30.61M | 16.37M | 9.72M | 10.56M | -7.91M | 2.60M | 9.80M | -26.75M | 4.71M |
| Net Income | 47.05M | 132.42M | 64.46M | -80.58M | 62.54M | 9.52M | 28.62M | 40.85M | 55.49M | 14.66M |
| Net Income growth (YoY) | -64.47% | +105.44% | — | -228.84% | +557.16% | -66.75% | -29.95% | -26.37% | +278.39% | -51.92% |
| EPS (Basic) | 1.52 | 4.29 | 2.10 | -2.68 | 2.14 | 0.33 | 1.01 | 1.45 | 1.99 | 0.53 |
| EPS (Diluted) | 1.51 | 4.25 | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 | 1.41 | 1.97 | 0.52 |
| Shares Outstanding (Basic) | 31.04M | 30.85M | 30.67M | 30.04M | 29.16M | 28.58M | 28.32M | 28.12M | 27.94M | 27.80M |
| Shares Outstanding (Diluted) | 31.15M | 31.15M | 31.55M | 30.04M | 32.22M | 29.46M | 29.50M | 28.89M | 28.17M | 27.96M |
| EBITDA | 119.77M | 216.93M | 136.80M | 86.11M | 126.21M | 64.05M | 97.80M | 89.83M | 67.01M | 58.16M |
| Gross Margin | 54.59% | 56.08% | 54.33% | 54.64% | 56.21% | 53.37% | 54.94% | 54.57% | 54.12% | 53.48% |
| Operating Margin | 7.46% | 15.33% | 9.69% | 6.70% | 10.86% | 5.33% | 8.28% | 8.29% | 5.89% | 4.93% |
| Net Margin | 3.42% | 10.13% | 5.18% | -7.71% | 6.19% | 110.00% | 3.00% | 4.75% | 6.97% | 1.92% |
This table shows 10 annual periods of CONMED's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CNMD's reporting calendar. What is a income statement?